Publications

APCaRI > Blog > Publications > Next-generation Sequencing of Urologic Cancers: Next Is Now

Publications

Next-generation Sequencing of Urologic Cancers: Next Is Now

By:
Contributors: Paul Boutros, PhD
Eur Urol. 2014 Jul;66(1):4-7. doi: 10.1016/j.eururo.2014.03.028. Epub 2014 Apr 5
Real FX1, Boutros PC2, Malats N3.

Abstract

The exomes/genomes of a few hundred kidney, bladder, and prostate tumours have been sequenced. This sequencing has unveiled new genes that are altered and new opportunities for tumour subclassification, prediction of outcome, and therapy. These opportunities will soon become realities.

 PubMed

Download PDF

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Recent Publications

Application of Surface-Enhanced Raman Spectroscopy to Guide Therapy for Advanced Prostate Cancer Patients Posted on Mar 13 22 at 11:10am
Analysis of the role of PI3K-AKT and DNA damage repair (DDR) genomic biomarkers as predictors of clinical outcomes in nonmetastatic castration-resistant prostate cancer (nmCRPC) Posted on Feb 16 22 at 11:47am
A prostate cancer risk calculator (PCRC-MRI): Use of clinical and magnetic resonance imaging data to predict biopsy outcome in North American men Posted on Feb 3 22 at 2:00pm

APCaRI Registry and Biorepository enrolls 1500th participant – 30% of our goal

We are pleased to announce that the Alberta Prostate Cancer Registry and Biorepository reached 30% of its accrual goal by enrolling participant 1,500! To date more than 100,000 biosamples are stored in the Canadian Research Biorepository along with comprehensive clinical data – all available for cutting edge research.

This was possible thanks to our wonderful team of clinical research personnel, clinicians and partners who have been working collaboratively to reach our goals!

If you are interested in accessing biospecimens or clinical information, let us know at catalina.vasquez@ualberta.ca

Samples available from participants with prostate cancer and age-matched men with negative biopsy
  • Serum (400uL/vial)
  • Plasma (400uL/vial)
  • Buffy Coat (~300uL/vial)
  • Red Blood Cells (400uL/vial)
  • Urine (400uL/vial)
  • Semen (~400uL/vial)
Clinical Information available
  • Demographic information and co-morbidities
  • Family history of prostate cancer
  • Pathology and diagnosis details
  • Clinical and pathological staging
  • Treatment history
  • Outcomes
  • Biospecimen collection, sample availability and processing details
- Unknown